表紙
市場調查報告書

數位活動趨勢:乳癌

Digital Landscape: Breast Cancer

出版商 GlobalData 商品編碼 703431
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
數位活動趨勢:乳癌 Digital Landscape: Breast Cancer
出版日期: 2018年09月12日內容資訊: 英文 155 Pages
簡介

本報告提供全球主要國家 (美國,及EUCAN加盟國 (加拿大,英國,德國,法國,義大利,西班牙) ,製藥企業為了促進乳癌治療藥的開發活動、啟發活動支援所致力的各種數位活動 - 品牌藥網站,非品牌藥的啟發活動,社群媒體/行動應用程式等 - 分析。

目錄

  • 摘要整理
  • 近幾年趨勢
  • 市場環境、分析
    • 美國:患者活動
    • 美國:HCP (醫療機關) 的活動
    • EUCAN:患者活動
    • EUCAN:HCP活動
  • 分析方法

分析對象企業:Pfizer,Novartis,AstraZeneca,Roche/Genentech,Eli Lilly,Eisai,Puma Technology,Celgene,R-Pharma,MidatechPharma,Kyowa Hakko Kirin,TerSera Therapeutics,Amgen

目錄
Product Code: GDHC044SP

"Digital Landscape: Breast Cancer", analyzes digital activities undertaken by pharma in support of therapies for Breast Cancer.

  • The report includes digital activities directed towards patients and/or HCPs
  • The geographic scope of the report is the United States, EUCAN(Canada and the 5EU countries: UK, Germany, France, Italy & Spain).
  • The main focus of the report is hormonal and targeted therapies, and certain branded chemotherapy drugs.

Key Highlights

  • US Patients: Strong digital support for US breast cancer patients in the US, particularly from Pfizer, Novartis and AstraZeneca. Most recent branded activity seen from Lilly and Novartis in the CDK4/6 inhibitor space. Most unbranded and social media activity focuses on supporting patients with metastatic breast cancer. Few breast cancer-specific mobile apps detected in the US.
  • US HCPs: There is little support for HCPs in the breast cancer space beyond branded. AstraZeneca, Genentech, Novartis and Pfizer offer examples of strong branded resources. The pharma-sponsored unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations. HCP-directed social media activity restricted to posts from corporate accounts.
  • EUCAN Patients: Good support for EUCAN breast cancer patients from pharma, particularly those in France. Support is weakest in the UK and Spain. Strong unbranded support but no multi-country, local-language campaigns seen. Majority of unbranded sites supported by social media. Good examples of pharma-sponsored mobile apps. Features include disease tracking and reminders, as well as emotional support.
  • EUCAN HCPs: Limited pharma-sponsored support for EUCAN HCPs in breast cancer, with most activity seen in Germany. The unbranded and mobile app landscapes are undeveloped, and like the US, partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Companies Mentioned: Pfizer, Novartis, AstraZeneca, Roche / Genentech, Eli Lilly, Eisai, Puma Technology, Celgene, R-Pharma, MidatechPharma, Kwoya Kirin, TerSera Therapeutics, Amgen.

Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for breast cancer.
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January 2017 - March 2018.

Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital breast cancer space, and can assist our pharma clients derive value in a number of ways.
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in breast cancer
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in breast cancer and beyond, and learn about key patient and physician online activities in breast cancer.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • >US: Patient-directed Activities
  • >US HCP-directed Activities
  • >EUCAN Patient-directed Activities
  • >EUCAN HCP-directed Activities
  • Methodology